Drug Search Results
More Filters [+]

Arasertaconazole

Alternative Names: arasertaconazole
Latest Update: 2013-10-09
Latest Update Note: Clinical Trial Update

Product Description

a azole antifungal that is FDA approved for the treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.  (Sourced from: https://drugs.ncats.io/drug/PR82C5R514)

Mechanisms of Action: Sterol Synthesis Inhibition,Fungal Growth Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Ferrer Internacional
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Arasertaconazole

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Candidiasis, Vulvovaginal

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

P-090756-01

P2

Completed

Candidiasis, Vulvovaginal

2011-03-01

2009-016655-21

P2

Completed

Candidiasis, Vulvovaginal

2010-11-15

Recent News Events

Date

Type

Title